-
Article | 2020.10.14
Covid-19: vaccine against SARS-CoV-2 infection, using the measles vector
Phase I testing in humans for the Institut Pasteur's SARS-CoV-2 vaccine candidate using the measles vector was lauchned in August 2020 in France and Belgium. Following the intermediate results of the Phase I clinical trial, the Institut Pasteur is stopping (January, 2021) development of the vaccine candidate based on the measles platform.
-
Article | 2017.01.05
MOOC Vaccinology - Institut Pasteur/Cnam
The objective of this course is to offer an integrated overview of vaccinology, from public health and scientific data justifying the development of a vaccine, to its delivery to the populations in the context of industrialized and developing countries.
-
Document de presse | 2007.12.11
A new candidate vaccine for dengue
Researchers from the Institut Pasteur and the CNRS have developed and demonstrated the validity of a new paediatric candidate vaccine against dengue. Their research, published in the journal PLoS Neglected Tropical Diseases, delivers promising results for the fight against this disease, which currently threatens a third of the world's population, and against which there is still no specific...
-
News | 2017.07.06
Why vaccines are essential
Health professionals are rallying around in support of the French government's plan to make 11 vaccines compulsory for children. Prof. Philippe Sansonetti, a microbiologist and infectious disease specialist at the Institut Pasteur, signed the petition launched by the French Society of Pediatricians, together with more than 1,600 colleagues* and infancy specialists. He reminds us that vaccines are...
-
News | 2019.06.18
Vaccines: a life insurance for humankind
France would be more suspicious of vaccines than more than 140 other countries, according to a global survey into how people around the world think and feel about science and major health challenges, published on June 19th, 2019. However, vaccines have made a key, cost-effective contribution to the prolongation of life expectancy and quality. Nowadays, vaccinology and immunology are facing...
-
Document de presse | 2016.08.02
Tuberculosis: a promising vaccine candidate
Scientists from the Institut Pasteur, working in collaboration with a team from Italy, have published the results of their research into the action mechanisms of a promising experimental tuberculosis (TB) vaccine in the journal PLOS Pathogens. BCG, the only currently approved TB vaccine, has been around for almost a century, but it is only partially effective and the protection it offers fades...
-
Document de presse | 2022.06.29
Rethinking the rabies vaccine
Rabies virus kills over 50,000 people each year. Although current rabies vaccines are effective, they do not offer lifelong protection and booster doses are required. Institut Pasteur scientists, in collaboration with researchers from La Jolla Institute for Immunology (LJI) in the United States, captured new high-resolution views of rabies virus, revealing potential vaccine targets. These...
-
Document de presse | 2007.01.31
The search for a streptococcus B vaccine
Streptococcus B, one of the primary sources of infection in newborns, can cause pneumonia, septicemia, and meningitis. Portuguese researchers and a team from the Institut Pasteur associated with the French National Centre for Scientific Research (CNRS) have identified a bacterial protein that modifies the host's immune system to facilitate bacterial colonization. The researchers, who have...
-
Article | 2020.10.14
Covid-19: A vaccine candidate using a lentiviral vector
This vaccine candidate for the SARS-CoV-2 virus, designed for nasal administration, demonstrated intense protection and extremely high production of antibodies and cytotoxic cell responses in preclinical trials.
-
News | 2021.07.15
BCG vaccine: the first tuberculosis vaccination took place a century ago
July 2021 marks the hundredth anniversary of the first vaccination of an infant with the BCG vaccine. Although tuberculosis is still one of the ten leading causes of mortality worldwide, this vaccine, developed at the Institut Pasteur, led to a steep reduction in the number of cases. We take a look back at how the vaccine was discovered.Albert Calmette arrived in Lille in 1897 as director of the...